Theravance Biopharma (TBPH) Free Cash Flow Growth (1y) (2014 - 2026)
Theravance Biopharma (TBPH) Free Cash Flow Growth (1y) (2014 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
88.70% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
-15.72% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
66.37% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
Theravance Biopharma |
846.10 Mn |
451.44 Mn |
- |
70.26% |
| Date | Value |
|---|
| Mar 31, 2026 |
70.26% |
| Dec 31, 2025 |
-456.04% |
| Sep 30, 2025 |
-24.89% |
| Jun 30, 2025 |
4,774.77% |
| Mar 31, 2025 |
3,966.94% |
| Dec 31, 2024 |
28.67% |
| Sep 30, 2024 |
-107.86% |
| Jun 30, 2024 |
66.50% |
| Mar 31, 2024 |
90.85% |
| Dec 31, 2023 |
98.77% |
| Sep 30, 2023 |
88.84% |
| Jun 30, 2023 |
8.07% |
| Mar 31, 2023 |
53.80% |
| Dec 31, 2022 |
-189.94% |
| Sep 30, 2022 |
51.66% |
| Jun 30, 2022 |
71.25% |
| Mar 31, 2022 |
63.26% |
| Dec 31, 2021 |
35.20% |
| Sep 30, 2021 |
41.22% |
| Jun 30, 2021 |
9.77% |
